What does Cognition Therapeutics, Inc. do?
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small…
What is Cognition Therapeutics, Inc.'s P/E and P/B ratio?
Cognition Therapeutics, Inc. has a P/E ratio of -4.1 and a P/B ratio of 2.02.
What is Cognition Therapeutics, Inc.'s debt-to-equity ratio?
Cognition Therapeutics, Inc. has a debt-to-equity ratio of 0.02.
How much does Cognition Therapeutics, Inc. owe compared with what it owns?
Cognition Therapeutics, Inc. owes $0.15 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Cognition Therapeutics, Inc.'s Positivity rank?
Cognition Therapeutics, Inc. is ranked #2,878 of 6,775 companies globally and #1,036 of 4,000 in United States on PositoAI, with a Positivity Score of 21,107.
Does Cognition Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Cognition Therapeutics, Inc..
Where can I read the latest news about Cognition Therapeutics, Inc.?
Recent headlines about Cognition Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Cognition Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Cognition Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.